Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
NNRTI (2nd generation)

Etravirine

Brand names: Intelence

Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with other antiretrovirals for treatment-experienced adults with HIV-1, including some NNRTI-resistant strains.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It binds directly and non-competitively to HIV-1 reverse transcriptase, inducing a conformational change that inhibits the enzyme and viral replication.

Prescribing in practice

  • Serious skin reactions, including Stevens-Johnson syndrome and hypersensitivity with systemic features, can occur, so it must be stopped if a severe rash or systemic hypersensitivity develops.
  • It is metabolised by and affects cytochrome P450 enzymes, leading to numerous drug interactions that require review.
  • Absorption is improved when taken after food, and it is used only as part of an optimised combination regimen.

Monitoring

Monitor HIV viral load and CD4 count, for rash or hypersensitivity, and review for drug interactions.

Counselling the patient

  • Take after a meal to ensure the medicine is absorbed properly.
  • Report any rash, especially with fever, blistering or mouth sores, without delay.
  • Tell your team about all other medicines you take.

Evidence & guidelines

Etravirine's efficacy in treatment-experienced patients was established in the DUET trials.

Reference: BHIVA guidelines; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Pathways